Back to Results
First PageMeta Content
Pharmacology / Medicine / Design of experiments / Evaluation methods / Bioethics / AZF / Clinical trial / Placebo / Adverse event / Clinical research / Research / Science


Mid-Cycle Memo - Isolagen Treatment
Add to Reading List

Open Document

File Size: 216,86 KB

Share Result on Facebook

Company

AEs / Autologous Human Fibroblasts Fibrocell Technologies Inc. / /

Country

United States / United Kingdom / /

Event

FDA Phase / /

IndustryTerm

telephone call assessment / dermal filler devices / final product / cellular product / fibroblast product / injection site / cell therapy product / nasolabial injection site / /

MedicalCondition

facial contour deformities / allergic reaction / DF / basal cell carcinoma / COPD / acne scars / scars / herpes / alopecia / erythema / numbness / pain / myocardial infarction / Injury / heart failure / urticaria / angioedema / Poisoning / atrial fibrillation / irritation / herniated disks / inflammation / MS / Infections / Injection Site Erythema / breast cancer / adenocarcinoma / /

MedicalTreatment

foot surgery / Restylane / cell therapy / Plastic surgery / /

Organization

Food and Drug Administration / Division of Epidemiology / Device Evaluation General and Plastic Surgery Devices Panel Public Advisory Committee / office of Device Evaluation General / office of Biostatistics and Epidemiology / /

Person

Craig E. Zinderman / Aileen G. Buckler / Rickey Wilson / Robert P. Wise / /

Position

investigator / Evaluator / Executive / Medical Officer / General / Chief / TBSB and Deputy Director / Director / JD Division / /

Product

Isolagen injections / R-002 / R-001 / United States / Section2 / R-003A / R-006 / /

Technology

cell therapy / /

URL

http /

SocialTag